Knorex is a Singapore-based Cayman issuer whose first year as a public company has already answered the question the listing was supposed to defer. The XPO advertising platform is a real product sold to agencies and brands, but the equity is now a residual claim on a business that lost nearly half its revenue when a single agency customer lost an automotive end-client to United States import tariffs. That concentration event, not the product story, is what the market is pricing. The investment debate is whether replacement volume and an equity line can keep the platform alive long enough for mix to matter, or whether listing status, cash, and customer concentration collapse into the same outcome.
The February pullback at the largest agency customer is the operating event that defines the year. That customer represented seventy-three percent of 2024 revenue and still forty-one percent of 2025 revenue even after the cut. The mechanism is simple and unforgiving. Agency contracts are non-exclusive and cancelable on short notice, so the loss of one automotive advertiser at the agency flowed straight through to Knorex without a contractual buffer. Management later stated that revenue excluding that automotive client rose twenty-one percent, which is the constructive case in a single clause: the rest of the book was not dying. The economic consequence is that fiscal 2025 revenue of $6 million is not a platform failure so much as proof that one relationship was the franchise. The prior-year print was $11 million.
The cash and listing facts convert that concentration event into an equity problem. Year-end cash of $129 thousand sat against a working-capital deficit measured in millions and an auditor paragraph that raises substantial doubt about going concern. NYSE American sent a late-filing notice in May after the company missed the extended annual-report deadline, then accepted the delayed filing in August. The March note and share-purchase package plugged the hole with $3 million of short-dated senior notes and a $50 million equity commitment that exists only if registration stays effective and buyers still want stock. Dilution is the price of survival. The tension is that every draw that funds payroll also teaches the market that the residual claim is a financing instrument first.
Three variables decide the next several quarters. Replacement of the lost agency volume is the first, because gross margin already expanded as low-quality spend left and still could not cover the cost base. Utilization of the share-purchase line versus further note or related-party borrowing is the second, because year-end cash cannot fund another year of double-digit-million operating burn. Continued listing on NYSE American after the August filing is the third, because a delisting would close the only cheap distribution channel the equity line needs. The share price near thirty-two cents against a $4 offering already assumes the first two stay unresolved. What flips the judgment is a print that shows the non-automotive book still compounding after the listing costs settle.